Industries > Pharma > Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Back to Pharma Reports

Global Osteoporosis Pharmaceutical and Nutraceutical Market 2020-2030

Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Forecasts by Type of Pharmaceuticals viz. Antiresorptive (Bisphosphonates, Selective Estrogen Receptor Modulator, Rank Ligand Inhibitors, Parathyroid Hormone and Others), Anabolic and Others, by Type of Nutraceutical (Minerals, Herbs and Phytochemicals, Dairy Products and Others), and Profiles of Leading Companies in Osteoporosis Pharmaceutical and Nutraceuticals and Regional and Leading National Market Analysis

PUBLISHED: 01 May 2020

PAGES: 338

PRODUCT CODE: PHA0722

SUBMARKET: Therapeutic Drugs

SKU: PHA0722 Categories: Pharma, Therapeutic Drugs Tags: PHA0722, PHA0973, PHA1151, PHA1154

Osteoporosis – Management of a global Challenge
Osteoporosis is a common disorder that is mostly common in the aging population and post- menopausal women. According to the International Osteoporosis Foundation, osteoporosis affects 1 in 4 women and more than 1 in 8 men over the age of 50 years, with 1 in 4 men and women having evidence of a vertebral fracture. The treatment and management of osteoporosis is a major challenge for healthcare workers and primary care givers. Numerous global and regional companies have been working on the R&D and production of various drugs and natural products called nutraceuticals for the treatment and management of osteoporosis. The Osteoporosis market was estimated to account for USD xyz bn in 2019 and is expected to grow with a CAGR of xyz% between 2020-2025.

To access the data contained in this document please email contactus@visiongain.com

The Osteoporosis Pharma and Nutra Market – Report Deliverables
Our 338-page report that includes 160 tables and 134 figures throws light on the pharmaceutical and nutraceutical market, the current market trends, new product launches, market estimates of the major therapeutic drug like antiresorptive, anabolic and Others with its different types in both global and regional markets. We also focus on the major types of nutraceuticals like minerals, herbals and phytochemicals, dairy products and others that are being widely prescribed and consumed for the management of osteoporosis. The report also includes invaluable insights and into how the COVID-19 pandemic will affect the market in the forecast period.

Osteoporosis Market – The Scope of the report
The current report is a vision for an array of information from market valuation, market trends, a SWOT of the market, leading regional and global market players and other similar information. Some of the scope includes:

• Market Estimation from 2020-2030 for global and regional market segmented further based on type of osteoporosis drugs, geographical region and countries.

• Market segmented based on the type of drugs
• Pharmaceuticals – It includes antiresorptive drugs which is further segmented into bisphosphonates, SERM, RLI, PH and Others. Major drugs like Fosamax, Boniva, Actonel, Aclasta, Evista, Duavee, Denosumab, Forteo, and many others are covered in the report. The anabolic drug like Evenity is also included in the report. Apart from them, drugs under clinical trials has also been covered in the report.
• Nutraceuticals – It includes the 4 major type of nutraceuticals like minerals, herbals and phytochemicals, dairy products and Others. The report covers 35 essential nutraceuticals like Calcium, Vitamins D, K, curcumin, embelin and others with global estimates forecast to 2030.

• Market segment based on the geographical distribution which includes
• USA
• Europe (UK, Germany, Italy, Spain and France)
• BRIC (Brazil, India, Russia, China)
• Japan
• Rest of the World

• Based on the leading companies
• Eli Lilly
• Amgen
• UCB
• GSK
• Merck and Co.
• Allergan
• Sanofi Aventis
• Pfizer
• Novartis
• Radius Health
• Zbiotics
• Kemin Europa
• Ajinomoto
• Herballife Nutrition
• Pharma Nord

• The report also includes the qualitative analysis (SWOT and STEP) for the osteoporosis pharmaceutical and nutraceutical market which enables the qualitative and quantitative analysis.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030: Forecasts by Type of Pharmaceuticals viz. Antiresorptive (Bisphosphonates, Selective Estrogen Receptor Modulator, Rank Ligand Inhibitors, Parathyroid Hormone and Others), Anabolic and Others, by Type of Nutraceutical (Minerals, Herbs and Phytochemicals, Dairy Products and Others), and Profiles of Leading Companies and Regional and Leading National Market Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview

1.1 Overview of the Osteoporosis Market 2020-2030

1.2 Who Should read this report?

1.3 How this study delivers

1.4 Questions answered by this Report

1.5 Who is this report for?

1.6 Methods of Research Analysis?

1.7 Frequently Asked Questions

1.8 Some Associated Reports

1.9 About Visiongain

2 Introduction to Osteoporosis Pharmaceutical and Nutraceutical Market

2.1 Market Definition

2.2 Osteoporosis Prevalence and Incidence

2.3 Osteoporosis: the dreaded disease

2.4 Osteoporosis : the Science

2.5 Types of Osteoporosis

2.6 Treatment of Osteoporosis

2.7 Osteoporosis Risk Factors

3 Global Osteoporosis Pharmaceutical Market 2020-2030

3.1 Osteoporosis Pharmaceutical Market, 2020-2030

3.1.1 Global Osteoporosis Therapeutics Market, By Type

3.1.1.1 Antiresorptive Drug Markets

3.1.1.2 Anabolic Drug Market

3.1.1.3 Others

3.1.2 Osteoporosis Pharmaceutical Market based on drug type (Antiresorptive) 2020-2030

3.1.2.1 Bisphosphonates

3.1.2.1.1 Alendronate

3.1.2.1.1.1 Fosamax

3.1.2.1.2 Ibandronate

3.1.2.1.2.1 Boniva

3.1.2.1.3 Risedronate

3.1.2.1.3.1 Actonel

3.1.2.1.4 Zoledronic Acid

3.1.2.1.4.1 Aclasta

3.1.2.1.5 Others

3.1.2.2 Selective Estrogen Receptor Modulator (SERM)

3.1.2.2.1 Bazedoxifene

3.1.2.2.2 Raloxifene

3.1.2.2.3 Others

3.1.2.3 Rank Ligand Inhibitors

3.1.2.4 Parathyroid Hormone Market

3.1.2.4.1 Forteo

3.1.2.4.2 Preotact

3.1.2.5 Others

3.1.3 Osteoporosis Pharmaceutical Drug – Based on Drug Type (Anabolic Drugs)

3.1.4 Osteoporosis Pharmaceutical Drug – Based on Drug Type (Other Drugs )

3.1.5 Clinical Trials

3.2 Osteoporosis Nutraceutical Market 2020-2030

3.2.1 Osteoporosis Nutraceutical Market, By Type 2020-2030

3.2.1.1 Minerals

3.2.1.2 Herbs and Phytochemicals

3.2.1.3 Dairy Products

3.2.1.4 Others

3.2.2 Osteoporosis Nutraceutical Market Based on Specific Products – 2020-2030

3.2.2.1 Butein

3.2.2.2 Calcium

3.2.2.3 Capsaicin

3.2.2.4 Cardamonin

3.2.2.5 Coronarin D

3.2.2.6 Curcumin (Turmeric)

3.2.2.7 Diosgenin

3.2.2.8 Embelin

3.2.2.9 Fisetin

3.2.2.10 Gambogic Acid

3.2.2.11 Genistein – soy/phytoestrogen (successful clinical trial)

3.2.2.12 Guggslterone

3.2.2.13 Harpagoside

3.2.2.14 Honokiol

3.2.2.15 Indole 3-carbinol

3.2.2.16 Isodeoxyelephantopin

3.2.2.17 L-citrulline

3.2.2.18 Lupeol

3.2.2.19 Lycopene

3.2.2.20 Muira puama

3.2.2.21 Oleanolic acid

3.2.2.22 Plumbagin

3.2.2.23 Quercetin

3.2.2.24 Resveratrol

3.2.2.25 Sulforaphane

3.2.2.26 Thiocolchioside

3.2.2.27 Vitamin D/Vitamin D3

3.2.2.28 Y-tocoterinol

3.2.2.29 Zyflamend

3.2.2.30 ACA

3.2.2.31 Piperine

3.2.2.32 Obovatol

3.2.2.33 Vitamin K

3.2.2.34 Theaflavin-3

3.2.2.35 Others

4 Global Osteoporosis Pharmaceutical and Nutraceutical Market – Based on Geography 2020-2030

4.1 USA

4.1.1 USA Thera Market

4.1.1.1 Reimbursement System in US

4.1.1.2 USA Need for Improvement in Prevention Measure

4.1.1.3 USA Osteoporosis Pharma Market, By Types

4.1.2 USA Nutra Market

4.1.2.1 USA Nutra Market, By Type

4.1.2.2 USA Nutraceuticals Marketing regulations

4.1.3 Drivers and Restraints

4.2 EU

4.2.1 Germany

4.2.1.1 Germany Thera Market

4.2.1.2 Germany Nutra Market

4.2.1.3 Drivers and Restraints

4.2.2 France

4.2.2.1 France Thera Market

4.2.2.2 France Nutra Market

4.2.2.3 Driver and restraints

4.2.3 UK

4.2.3.1 UK Thera Market

4.2.3.2 UK Nutra Market

4.2.3.3 Drivers and Restraints

4.2.4 Italy

4.2.4.1 Italy Thera Market

4.2.4.2 Italy Nutra Market

4.2.4.3 Driver and restraints

4.2.5 Spain

4.2.5.1 Spain Thera Market

4.2.5.2 Spain Nutra Market

4.2.5.3 Drivers and Restraints

4.3 BRIC

4.3.1 China

4.3.1.1 China Thera Market

4.3.1.2 China Nutra Market

4.3.1.3 Drivers and Restraints

4.3.2 India

4.3.2.1 India Thera Market

4.3.2.2 India Nutra Market

4.3.2.3 Drivers and restraints

4.3.3 Russia

4.3.3.1 Russia Thera Market

4.3.3.2 Russia Nutra Market

4.3.3.3 Drivers and restraints

4.3.4 Brazil

4.3.4.1 Brazil Thera Market

4.3.4.2 Brazil Nutra Market

4.3.4.3 Drivers and restraints

4.4 Japan

4.4.1 Japan Thera Market

4.4.2 Japan Nutra Market

4.4.3 Drivers and Restraints

4.5 ROW

4.5.1 RoW Thera Market

4.5.2 RoW Nutra Market

4.5.3 Drivers and Restraints

5 Company Profiles

5.1 Eli Lilly

5.2 Amgen

5.3 UCB

5.4 GSK

5.5 Merck and Co.

5.6 Allergan

5.7 Sanofi Avenitis

5.8 Pfizer

5.9 Novartis

5.10 Radius Health

5.11 Zbiotics

5.12 Kemin Europa

5.13 Ajinomoto

5.14 Herbalife Nutrition

5.15 Pharma Nord

6 Qualitative Analysis

6.1 SWOT

6.2 STEP

7 Covid-19 Impact and the Osteoporosis Pharmaceutical and Nutraceutical Market

8 Conclusions

9 Associated Visiongain Reports

10 Visiongain Report Sales Order Form

11 About Visiongain

12 Visiongain Report Evaluation Form

List of Tables

1. Table 2.1 Mechanisms Involved in Bone Grafting

2. Table 2.2 Research Patents for Potential Osteoporosis Pharmaceuticals and nutraceuticals, 2019

3. Table 3.1. Global Osteoporosis Pharma and Nutra Market, 2020-2030, (in USD Bn), AGR (%),

4. Table 3.2. Treatment for Osteoporosis, by Therapeutics, drug category, Branded Names for most important drugs, 2020

5. Table 3.3. Global Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

6. Table 3.4. Global Osteoporosis Pharma Market, Based on Type 2020-2030, Market Share (in %)

7. Table 3.5. Global Osteoporosis Antiresorptive Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

8. Table 3.6. Global Osteoporosis Anabolics Market, 2020-2030, (in USD Bn), AGR (%), CAGR (%)

9. Table 3.7. Global Osteoporosis Others Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

10. Table 3.8. Global Osteoporosis Market (Antiresorptive), By types

11. Table 3.9. Global Osteoporosis Bisphosphonate Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

12. Table 3.10. Global Osteoporosis Alendronate Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

13. Table 3.11. Global Osteoporosis Ibandronate Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

14. Table 3.12. Global Osteoporosis Risedronate Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

15. Table 3.13. Global Osteoporosis Zoledronic Acid Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

16. Table 3.14. Global Osteoporosis Other Bisphosphonate Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

17. Table 3.15. Global Osteoporosis SERM Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

18. Table 3.16. Global Osteoporosis Market (SERM), By types

19. Table 3.17. Global Osteoporosis Bazedoxifene Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

20. Table 3.18. Global Osteoporosis Raloxifene Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

21. Table 3.19. Global Osteoporosis Others SERM Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

22. Table 3.20. Global Osteoporosis Rank Ligand Inhibitors Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

23. Table 3.21. Global Osteoporosis Parathyroid Hormone Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

24. Table 3.22. Global Osteoporosis Bisphosphonate Others Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

25. Table 3.23. Global Osteoporosis Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

26. Table 3.24. Global Osteoporosis Nutraceuticals Market, By types

27. Table 3.25. Global Osteoporosis Mineral Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

28. Table 3.26. Global Osteoporosis Herbs and Phytochemical Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

29. Table 3.27. Global Osteoporosis Dairy Product Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

30. Table 3.28. Global Osteoporosis Other Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

31. Table 3.29. Global Osteoporosis Butein Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

32. Table 3.30. Global Osteoporosis Calcium Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

33. Table 3.31. Global Osteoporosis Capsaicin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

34. Table 3.32. Global Osteoporosis Cardamonin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

35. Table 3.33. Global Osteoporosis Coronarin D Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

36. Table 3.34. Global Osteoporosis Curcumin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

37. Table 3.35. Global Osteoporosis Diosgenin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

38. Table 3.36. Global Osteoporosis Embelin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

39. Table 3.37. Global Osteoporosis Fistein Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

40. Table 3.38. Global Osteoporosis Gambogic Acid Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

41. Table 3.39. Global Osteoporosis Genistein Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

42. Table 3.40. Global Osteoporosis Guggulsterone Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

43. Table 3.41. Global Osteoporosis Harpagoside Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

44. Table 3.42. Global Osteoporosis Honokiol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

45. Table 3.43. Global Osteoporosis Indole-3-Carbinol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

46. Table 3.44. Global Osteoporosis IDET Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

47. Table 3.45. Global Osteoporosis L-citrulline Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

48. Table 3.46. Global Osteoporosis Lupeol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

49. Table 3.47. Global Osteoporosis Lycopene Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

50. Table 3.48. Global Osteoporosis Muira Puama Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

51. Table 3.49. Global Osteoporosis OA Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

52. Table 3.50. Global Osteoporosis Plumbagin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

53. Table 3.51. Global Osteoporosis Quercetin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

54. Table 3.52. Global Osteoporosis resveratol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

55. Table 3.53. Global Osteoporosis sulforaphane Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

56. Table 3.54. Global Osteoporosis Thiocolchicoside Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

57. Table 3.55. Global Osteoporosis Vitamin D Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

58. Table 3.56. Global Osteoporosis Y-Tocoterinol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

59. Table 3.57. Global Osteoporosis Zyflamend Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

60. Table 3.58. Global Osteoporosis ACA Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

61. Table 3.59. Global Osteoporosis Piperine Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

62. Table 3.60. Global Osteoporosis Obovatol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

63. Table 3.61. Global Osteoporosis Vitamin K Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

64. Table 3.62. Global Osteoporosis TF Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

65. Table 3.63. Global Osteoporosis Others Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

66. Table 4.1. Global Market Share of Osteoporosis Pharma and Nutra Market, By Region, 2020-2030

67. Table 4.2. USA Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

68. Table 4.3. USA Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

69. Table 4.4. USA Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

70. Table 4.5. USA Osteoporosis Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

71. Table 4.6. USA Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

72. Table 4.7. EU5 Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

73. Table 4.8 The Median Ages in EU5 Nations from 1960 to 2060, by Country

74. Table 4.9. European Union Osteoporosis Market , Market Share based on Region, 2020-2030

75. Table 4.10. Germany Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

76. Table 4.11. Germany Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

77. Table 4.12. Germany Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

78. Table 4.13. Germany Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

79. Table 4.14. Germany Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

80. Table 4.15. France Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

81. Table 4.16. France Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

82. Table 4.17. France Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

83. Table 4.18. France Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

84. Table 4.19. France Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

85. Table 4.20. UK Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

86. Table 4.21. UK Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

87. Table 4.22. UK Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

88. Table 4.23. UK Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

89. Table 4.24. UK Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

90. Table 4.25. Italy Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

91. Table 4.26. Italy Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

92. Table 4.27. Italy Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

93. Table 4.28. Italy Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

94. Table 4.29. Italy Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

95. Table 4.30. Spain Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

96. Table 4.31. Spain Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

97. Table 4.32. Spain Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

98. Table 4.33. Spain Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

99. Table 4.34. Spain Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

100. Table 4.35. BRIC Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

101. Table 4.36. BRIC Osteoporosis Market, Market Share based on Region, 2020-2030

102. Table 4.37. China Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

103. Table 4.38. China Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

104. Table 4.39. China Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

105. Table 4.40. China Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

106. Table 4.41. China Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

107. Table 4.42. India Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

108. Table 4.43. India Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

109. Table 4.44. India Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

110. Table 4.45. India Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

111. Table 4.46. India Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

112. Table 4.47. Russia Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

113. Table 4.48. Russia Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

114. Table 4.49. Russia Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

115. Table 4.50. Russia Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

116. Table 4.51. Russia Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

117. Table 4.52. Brazil Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

118. Table 4.53. Brazil Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

119. Table 4.54. Brazil Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

120. Table 4.55. Brazil Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

121. Table 4.56. Brazil Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

122. Table 4.56. Brazil Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

123. Table 4.57. Japan Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

124. Table 4.58. Japan Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

125. Table 4.59. Japan Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

126. Table 4.60. Japan Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

127. Table 4.61. Japan Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

128. Table 4.62. RoW Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

129. Table 4.63. RoW Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

130. Table 4.64. RoW Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

131. Table 4.65. RoW Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

132. Table 4.66. RoW Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

133. Table 5.1. Eli Details Company Details, 2019

134. Table 5.1.2. Company Financials

135. Table 5.3. Eli Lilly Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

136. Table 5.4. Amgen Details Company Details, 2019

137. Table 5.5 Company Financials

138. Table 5.6. Amgen Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

139. Table 5.7. UCB Details Company Details, 2019

140. Table 5.8 Company Financials

141. Table 5.9. UCB Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

142. Table 5.10. GSK Details Company Details, 2019

143. Table 5.11 Company Financials

144. Table 5.12. Merck Details Company Details, 2019

145. Table 5.13 Company Financials

146. Table 5.14. Allergan Details Company Details, 2019

147. Table 5.15 Company Financials

148. Table 5.16. Sanofi Details Company Details, 2019

149. Table 5.17 Company Financials

150. Table 5.18.Pfizer Details Company Details, 2019

151. Table 5.19 Company Financials

152. Table 5.20. Pfizer Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

153. Table 5.21.Novartis Details Company Details, 2019

154. Table 5.22 Company Financials

155. Table 5.23. Radius Health Details Company Details, 2019

156. Table 5.24 Company Financials

157. Table 6.1 Strengths and Weaknesses of the Osteoporosis Market, 2020-2030

158. Table 6.2 Opportunities and Threats to the Osteoporosis Market, 2020-2030

159. Table 6.3 Social and Technological Factors of the Osteoporosis Market, 2020-2030

160. Table 8.4 Economic and Political Factors of the Osteoporosis Market, 2016-2026

List of Figures

1. Figure 2.1. Global Vertebral Fracture market share, 2019

2. Figure 3.1. Global Osteoporosis Pharma and Nutra Market, (in USD Mn), AGR (%)

3. Figure 3.2. Global Osteoporosis Therapeutics Market, (in USD mn), 2020-2030, AGR (%)

4. Figure 3.3. Global Osteoporosis Pharma Masrket, Based on Type, Market Share (in%), 2019, 2020, 2030

5. Figure 3.4. Global Osteoporosis Antiresorptive Market, 2020-30, (in USD Mn), AGR (%)

6. Figure 3.5. Global Osteoporosis Anabolic Drug Market, 2020-2030 (in USD Mn), AGR(%)

7. Figure 3.6 Global Osteoporosis Others Drug Market, 2020-2030 (in USD Mn), AGR (%)

8. Figure 3.8. Global Osteoporosis Bisphosphonate Market, 2020-2030, (IN USD Mn), AGR(%)

9. Figure 3.9. Global Osteoporosis Alendronate Market, 2020-2030, (in USD Mn), AGR (%)

10. Figure 3.10. Global Osteoporosis Ibandronate Market, 2020-2030, (in USD Mn), AGR(%)

11. Figure 3.11. Global Osteoporosis Risedronate Market , 2020-2030 (in USD Mn), AGR (%)

12. Figure 3.12. Global Osteoporosis Zoledronic Acid Market, 2020-2030 (in USD Mn), AGR (%)

13. Figure 3.13. Global Osteoporosis Other Bisphosphonate Market, 2020-2030 (in USD Million), AGR(%)

14. Figure 3.14 Global Osteoporosis SERM Market, 2020-2030 (in USD Mn), AGR (%)

15. Figure 3.16 global Osteoporosis Bezedoxifene Market, 2020-2030, (in USD Mn), AGR(%)

16. Figure 3.17 Global Osteoporosis Raloxifene Market, 2020-2030 (in USD Mn), AGR(%)

17. Figure 3.18 Global Osteoporosis SERM Market, 2020-2030 (in USD Mn), AGR(%)

18. Figure 3.19 Global Osteoporosis RLI Market, 2020-2030, (in USD Mn), AGR(%)

19. Figure 3.20 Global Osteoporosis PH Market 2020-2030 (in USD Mn), AGR(%)

20. Figure 3.21. Global Osteoporosis Bisphosphonate Others Market, 2020-2030 (in USD Mn), AGR(%)

21. Figure 3.22. Global Osteoporosis Nutraceutical Market, 2020-2030 (in USD Mn), AGR(%)

22. Figure 3.23 Global Osteoporosis Nutraceutical Market, By Type 2020

23. Figure 3.24 Global Osteoporosis Mineral Nutra Market, 2020-2030 (in USD Mn), AGR(%)

24. Figure 3.25 Global Osteoporosis Herbs and Phytochemical Nutra Market, 2020-2030 (in USD Mn), AGR(%)

25. Figure 3.26. Global Osteoporosis Dairy Product Nutra Market, 2020-2030 (In USD Mn), AGR(%)

26. Figure 3.27. Global Osteoporosis Other Nutra Market 2020-2030 (in USD Mn), AGR(%)

27. Figure 3.28. Global Osteoporosis Butein Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

28. Figure 3.29. Global Osteoporosis Calcium Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

29. Figure 3.30. Global Osteoporosis Capsaicin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

30. Figure 3.31 Global Osteoporosis Cardamonin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

31. Figure 3.32. Global Osteoporosis Coronarin D Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

32. Figure 3.33. Global Osteoporosis Curcumin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

33. Figure 3.34. Global Osteoporosis Diosgenin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

34. Figure 3.35. Global Osteoporosis Embelin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

35. Figure 3.36. Global Osteoporosis Fistein Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

36. Figure 3.37. Global Osteoporosis Gambogic Acid Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

37. Figure 3.38. Global Osteoporosis Genistein Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

38. Figure 3.39. Global Osteoporosis Guggulsterone Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

39. Figure 3.40. Global Osteoporosis Harpagoside Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

40. Figure 3.41. Global Osteoporosis Honokiol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

41. Figure 3.42. Global Osteoporosis Indole-3-Carbinol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

42. Figure 3.43. Global Osteoporosis IDET Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

43. Figure 3.44. Global Osteoporosis L-citrulline Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

44. Figure 3.45. Global Osteoporosis Lupeol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

45. Figure 3.46. Global Osteoporosis Lycopene Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

46. Figure 3.47. Global Osteoporosis Muira Puama Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

47. Figure 3.48. Global Osteoporosis OA Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

48. Figure 3.49. Global Osteoporosis Plumbagin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

49. Figure 3.50. Global Osteoporosis Quercetin Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

50. Figure 3.51. Global Osteoporosis resveratol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

51. Figure 3.52. Global Osteoporosis sulforaphane Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

52. Figure 3.53. Global Osteoporosis Thiocolchicoside Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

53. Figure 3.54. Global Osteoporosis Vitamin D Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

54. Figure 3.55. Global Osteoporosis Y-Tocoterinol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%),

55. Fiigure 3.56. Global Osteoporosis Zyflamend Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

56. Figure 3.57. Global Osteoporosis ACA Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

57. Figure 3.58. Global Osteoporosis Piperine Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

58. Figure 3.59. Global Osteoporosis Obovatol Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

59. Figure 3.60. Global Osteoporosis Vitamin K Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

60. Figure 3.61. Global Osteoporosis TF Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

61. Figure 3.62. Global Osteoporosis Others Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

62. Figure 4.1. Global Market Share of Osteoporosis Pharma and Nutra Market, By Region, 2020-2030

63. Figure 4.2. USA Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

64. Figure 4.3. USA Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%)

65. Figure 4.4. USA Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%)

66. Figure 4.5. USA Osteoporosis Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

67. Figure 4.6. USA Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

68. Figure 4.7 Drivers and Restraints

69. Figure 4.8 EU5 Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

70. Figure 4.9. European Union Osteoporosis Market , Market Share based on Region, 2020-2030

71. Figure 4.10. Germany Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

72. Figure 4.11. Germany Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

73. Figure 4.12. Germany Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

74. Figure4.13. Germany Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

75. Figure 4.14. Germany Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

76. Figure 4.15. France Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

77. Figure 4.16. France Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

78. Figure 4.17. France Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

79. Figure 4.18. France Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

80. Figure 4.19. France Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

81. Figure 4.20. France Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

82. Figure 4.21. UK Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

83. Figure 4.22. UK Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

84. Figure 4.23. UK Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

85. Figure 4.24. UK Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

86. Figure 4.25. Italy Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

87. Figure 4.26. Italy Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

88. Figure 4.27. Italy Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

89. Figure 4.28. Italy Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

90. Figure 4.29. Italy Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

91. Figure 4.30. Spain Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

92. Figure 4.31. Spain Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

93. Figure 4.32. Spain Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

94. Figure 4.33. Spain Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

95. Figure 4.34. Spain Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

96. Figure 4.35. BRIC Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

97. Figure 4.36. BRIC Osteoporosis Market, Market Share based on Region, 2019

98. Figure 4.37. China Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

99. Figure 4.38. China Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

100. Figure 4.39. China Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

101. Figure 4.40. China Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

102. Figure 4.41. China Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

103. Figure 4.42. India Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

104. Figure 4.43. India Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

105. Figure 4.44. India Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

106. Figure 4.45. India Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

107. Figure 4.46. India Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

108. Figure 4.47. Russia Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

109. Figure 4.48. Russia Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

110. Figure 4.49. Russia Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

111. Figure 4.50. Russia Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

112. Figure 4.51.Russia Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

113. Figure 4.52. Brazil Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

114. Figure 4.53. Brazil Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

115. Figure 4.54. Brazil Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

116. Figure 4.55. Brazil Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

117. Figure 4.56. Brazil Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

118. Figure 4.57. Japan Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

119. Figure 4.58. Japan Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

120. Figure 4.59. Japan Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

121. Figure 4.60. Japan Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

122. Figure 4.61. Japan Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

123. Figure 4.62. RoW Osteoporosis Pharma and Nutraceutical Market, 2020-2030, (in USD Mn), AGR (%)

124. Figure 4.63. RoW Osteoporosis Pharma Market, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

125. Figure 4.64. RoW Osteoporosis Pharma Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

126. Figure 4.65. RoW Osteoporosis Nutra Market, 2020-2030, (in USD Mn), AGR (%)

127. Figure 4.66. RoW Osteoporosis Nutra Market, By Type, 2020-2030, (in USD Mn), AGR (%), CAGR (%)

128. Figure 5.1. Eli Lilly Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

129. Figure 5.2. Amgen Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

130. Figure 5.3. UCB Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

131. Figure 5.4. Pfizer Osteoporosis Drug Sales Forecast, 2020-2030, (in USD Mn)

132. Figure 7.1. Global Osteoporosis Market – Based on market share, 2019 (in %)

133. Figure 7.2. Global Osteoporosis Pharmaceutical Market Share, 2019

134. Figure 7.3. Global Osteoporosis nutraceutical market share, 2019

Download sample pages

Complete the form below to download your free sample pages for Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Download sample pages

Complete the form below to download your free sample pages for Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.

27 September 2023

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.

25 September 2023

READ

Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033

The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.

21 September 2023

READ

Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033

The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.

14 September 2023

READ

Industries > Pharma > Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Back to Pharma Reports

Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Download sample pages

Related reports

Automation in Biopharma Industry 2020-2030

Clinical Trial Supply and Logistics Market for Pharma 2020-2030

Active Pharmaceutical Ingredient Market Report 2020-2030

Global Pharmaceutical Blockchain Market Research Report 2020-2030

Pharmaceutical Spray Drying Market Report 2021-2031

Pharmacy Inventory Management Software Market Report 2020-2030

Pharmaceutical Analytical Testing Outsourcing Market Report 2020-2030

Pharmaceutical Contract Manufacturing Market 2019-2029

Top 30 Pharmaceutical Wholesale & Distribution Organizations 2019

Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033

Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033

Our Clients